Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent Lymphoma
JCO Oncology Practice · 2023-12 · 19 (12) · 1168-1178
DOI: 10.1200/op.23.00336 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2023-12. Verfasst von Chia Jie Tan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Multiple Myeloma, Lymphoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Treatment options for myeloma and indolent lymphoma are increasing exponentially, with distinct efficacy, side effects, and cost. We aim to determine the factors influencing patient and caregiver treatment preferences. METHODS Patients and caregivers of patients with myeloma and indolent lymphoma were recruited from two cancer centers in Singapore. Preferences were elicited using a discrete choice experiment. Attributes and levels were selected based on a previous qualitative study. The relative preference for levels within each attribute (part worth utility values) and the extent to which an attribute would influence decision making (relative importance) were calculated. Patient and caregiver participation in the treatment plan selection process were assessed using the Control Preference Scale. RESULTS One hundred ninety-nine patients and 169 caregivers were recruited. Patients placed the highest importance on out-of-pocket costs (relative importance = 35%), followed by efficacy (25%), persistent side effects (19%), administration route (8%), treatment duration (7%), and short-term side effects (5%). Caregivers ranked efficacy (27%) as the most important attribute, over out-of-pocket costs (24%). Most patients preferred a collaborative role in the shared decision-making process, while similar proportions of caregivers favored active and collaborative roles. CONCLUSION Our study demonstrates that both patients and caregivers consider cost seriously when making treatment decisions. Furthermore, as patient and caregiver preferences may differ, there are implications for treatment selection and counseling, especially in cultures where caregivers have more prominent roles in treatment planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy, National University of Singapore, Singapore, Singapore.
- Department of Haematology, Singapore General Hospital, Singapore, Singapore.
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
- Department of Medicine, National University of Singapore, Singapore, Singapore.
- Research for Impact, Singapore, Singapore.
- Behavioral and Implementation Science Interventions, National University of Singapore, Singapore, Singapore.
ORCID-Profile: Chia Jie Tan, Chandramouli Nagarajan, Wee Joo Chng, Yen-Lin Chee, Melissa Ooi, Yunxin Chen, Xin Yi Wong, Wei-Ying Jen
Zitieren
APA
Tan, C. J., Tan, M. S. Y., Nagarajan, C., Chng, W. J., Chee, Y. L., Ooi, M., Ng, L. C. K., Chen, Y., Yoong, J. S. Y., Wong, X. Y., & Jen, W. Y. (2023). Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent Lymphoma. JCO Oncology Practice, 19(12), 1168-1178. https://doi.org/10.1200/op.23.00336
Vancouver
Tan CJ, Tan MSY, Nagarajan C, Chng WJ, Chee YL, Ooi M, et al. Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent Lymphoma. JCO Oncology Practice. 2023;19(12):1168-1178. doi:10.1200/op.23.00336
BibTeX
@article{Tan2023,
author = {Tan, Chia Jie and Tan, Melinda Si Yun and Nagarajan, Chandramouli and Chng, Wee Joo and Chee, Yen-Lin and Ooi, Melissa and Ng, Lawrence Cheng Kiat and Chen, Yunxin and Yoong, Joanne Su Yin and Wong, Xin Yi and Jen, Wei-Ying},
title = {Factors Affecting Patient and Caregiver Preferences for Treatment of Myeloma and Indolent Lymphoma},
journal = {JCO Oncology Practice},
year = {2023},
volume = {19},
number = {12},
pages = {1168--1178},
doi = {10.1200/op.23.00336}
}
EUVIMED